

ing further investigation. All channels of supply have been notified of this decision.

We feel we would be remiss if we failed to express in this letter, our sincere thanks for your acceptance of Orabilex, and for your confidence in us as expressed in the many letters we have received. We consider ourselves to be dedicated to the research and investigation of products of service in radiology.

With renewed assurances of our desire to be of service to you, we remain

Sincerely yours,

C. H. BRADNEY,
Executive Vice President.

ABBOTT LABORATORIES,
North Chicago, Ill., April 24, 1967.

DEAR DOCTOR: Attached is a duplicate of a letter we recently sent you on Eutonyl™ (pargyline hydrochloride). Because of the importance of the subject matter, we urge you to read it, if you happened to miss the original.

It places in perspective recent medical information on Eutonyl—and may answer any questions you may have regarding the current status of Eutonyl in treatment of hypertension.

Many thanks in advance for your interest.

Sincerely,

W. D. PRATT,
Professional Services.

P.S.—Also please note the reply card. It will bring a generous supply of samples. Simply sign and mail.

ABBOTT LABORATORIES,
NORTH CHICAGO, ILL.

DEAR DOCTOR: We hope in this letter to clear up any confusion you may have had regarding our recent precautionary letter on Eutonyl™ (pargyline hydrochloride).

Recently, we asked the F.D.A. for permission to include in our literature new precautions relating to ingestion of cheese and also certain statements reemphasizing the need for caution in use of sympathomimetic drugs in patients taking Eutonyl. We also asked to be permitted to send physicians a letter outlining our recommended changes. This permission was granted on Wednesday, February 26, and our letter went into the mail two days later.

That same week, however, doctors were receiving a letter from another manufacturer announcing *withdrawal* (under protest) of another drug from the market. That drug, of course, was Parnate® (tranlycypromine).

We've learned now that the near simultaneous release of the letters has caused some confusion. In fact, quite a few reports have come to us that some physicians have concluded that Eutonyl was taken off the market.

Please be assured that Eutonyl is very much in the market.

The other drug, Parnate, was used for treatment of mental depression. Eutonyl is a drug for *hypertension*.

Below, we've summarized the *important changes* in the literature. The Comment in each case will help put this material in perspective.

1. We have added a contraindication against cheese. This is a result of hypertensive reactions in some patients on Eutonyl who have eaten aged or nonprocessed cheese.

Comment: We have received only 12 such reports. There may have been a few other cheese reactions, of course, which have not been reported to Abbott. The reactions are due to the presence of tyramine in certain types of cheese. Until more information is known about these cheese reactions, we can not recommend any "exceptions" to the rule of not eating cheese.

2. We are reemphasizing the possibility of *hypertensive* reactions in patients on Eutonyl who are given a centrally or peripherally acting sympathomimetic drug (e.g. amphetamine or ephedrine). Included are certain over-the-counter drugs—cold preparations, reducing pills, etc.—products that might contain amphetamine, ephedrine, or their derivatives.

Comment: The number of such reports is quite small—less than 15 out of an estimated 1,700,000 drug uses in some 400,000 different patients. (A "drug use" is any occasion in which the drug is prescribed or dispensed.) The important point is that these hypertensive reactions are avoidable. With the